Head-to-head

Ivim Health vs TMates

Compared on both medications across the eight dimensions this database records. They differ on 6 of those eight. TMates is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.

The short answer

Ivim Health is $353 a month all-in for tirzepatide; TMates is $297. Over twelve months that is $4,236 against $2,004. Value Scores are 46.3 and 55.3 out of 100.

Tirzepatide

Plan pages: Ivim Health plans · TMates plans

At 10 mg/week, Ivim Health is $353 a month all-in and TMates is $297 — $56 apart, or $672 across a year. Over twelve months the totals are $4,236 (billed monthly) and $2,004 (prepaid term).

Ivim Health prices tirzepatide by dose: $208 per month at 2.5 mg rising to $278 at 10 mg, a difference of $70 a month between the bottom and top of the ladder. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.

TMates charges a flat $297 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.

2.557.51012.515mg/week$208$278
Ivim Health in petrol against TMates in graphite — all-in monthly tirzepatide cost at each dose. Second line: TMates.
All-in monthly tirzepatide cost at each published dose, with each program's rank among everyone publishing at that dose
DoseIvim HealthRankTMatesRankCheaper
2.5 mg$20810/31$29716/31Ivim Health by $89
5 mgneither publishes
7.5 mgneither publishes
10 mg$2787/27$29712/27Ivim Health by $19
12.5 mgneither publishes
15 mgneither publishes

TMates is cheaper at every dose where both publish a price, so the lead does not change as you titrate.

Across the 27 programs this database can rank on tirzepatide, Ivim Health sits 16 of 27 on all-in monthly cost and TMates sits 10. There are 5 other programs priced between them. The field median is $339 and the floor is $169, so TMates is below the median and the other is above it. Ivim Health is $184 above the cheapest tirzepatide program on record. TMates is $128 above the cheapest tirzepatide program on record.

LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — Ivim Health undercuts it by $96, TMates by $152. Compounded products are not FDA approved; insurance can reverse that comparison.

Published tirzepatide rates per month on each plan term
Plan termIvim HealthTMatesCheaper
Month to month$278$297Ivim Health by $19
12-month term$167only TMates publishes this term
Twelve months of tirzepatide if you settled at each dose
Settled doseIvim HealthTMatesDifference
2.5 mg$3,396$3,564$168 apart
10 mg$4,236$3,564$672 apart

Ivim Health publishes no rate for 3-month term, 6-month term, 12-month term; TMates publishes none for 3-month term, 6-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.

A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $4,166 on Ivim Health and $3,564 on TMates — $602 apart, and a different gap from the $672 you would get by multiplying the monthly difference by twelve. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.

That calculation is partial: Ivim Health publishes no price at 2 of the 6 doses and TMates publishes no price at 2 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.

Value Scores are 46.3 for Ivim Health and 55.3 for TMates, against a tirzepatide category floor of $169. TMates leads by 9.0 points, driven mostly by price.

Tirzepatide Value Score components
ProgramPrice /70Evidence /15Dose /10Membership /5Total /100
Ivim Health33.512.80046.3
TMates39.810.50555.3

Semaglutide

Plan pages: Ivim Health plans · TMates plans

At 2.4 mg/week, Ivim Health is $224 a month all-in and TMates is $249 — $25 apart, or $300 across a year. Over twelve months the totals are $2,688 (billed monthly) and $1,896 (prepaid term).

Ivim Health charges a flat $149 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.

TMates charges a flat $249 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.

0.250.511.72.4mg/week$149$149
Ivim Health in petrol against TMates in graphite — all-in monthly semaglutide cost at each dose. Second line: TMates.

Ivim Health is cheaper at every dose where both publish a price, so the lead does not change as you titrate.

Value Scores are 53.1 for Ivim Health and 51.8 for TMates, against a semaglutide category floor of $129. Ivim Health leads by 1.3 points, driven mostly by price.

Where the two programs differ

All-in monthly

TMates is cheaper month to month — $297 against $353, a gap of $56 every month, or $672 across a year if both rates hold.

Cancellation terms

Cancellation differs: Ivim Health states Cancel anytime, while TMates states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.

Commitment

Ivim Health asks for Month-to-month; TMates asks for 12-month plan or month-to-month; substantial difference in rates. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.

Evidence status

The two prices are not equally well evidenced. Ivim Health's figure is provider-stated and TMates's is reported. Ivim Health rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.

Membership fee

Ivim Health charges a membership of $75 a month on top of the medication. That is already folded into the all-in figures above — it is broken out here because a membership is a recurring charge that continues even in a month you skip a shipment.

Twelve-month cost

Over twelve months the totals are $4,236 for Ivim Health and $2,004 for TMates. TMates is lower by $2,232 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.

Dose policy

Both price by dose, so both advertised figures understate the cost of a titration year. Compare the ladders above rather than the headline rates.

Shipping

Shipping is handled the same way by both — included in the quoted price.

What each record says

Ivim Health Official site

Ivim combines a $75/month membership with tiered medication pricing; its all-in semaglutide figure ($149) is competitive, while tirzepatide lands mid-pack at $278 all-in at the 10 mg basis.

It does not publicly name its compounding pharmacy; the record shows Partner pharmacies, so who actually makes the medication cannot be independently verified; commitment terms are Month-to-month; cancellation is Cancel anytime; availability is stated as ~50 states.

Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — ivimhealth.com pricing captures 2026-08-05

Watch: Dose-tiered tirzepatide means the advertised start price understates maintenance cost; compare on the maintenance column.

TMates Official site

TMates is a compounded GLP-1 telehealth service that includes medication and visits in one bundled monthly price. It offers both semaglutide and tirzepatide, with a 12-month plan that brings tirzepatide to $167/mo — the lowest committed-plan figure for tirz outside of bmiMD and NexLife.

It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are 12-month plan or month-to-month; substantial difference in rates; cancellation is Per provider terms; availability is stated as Confirm at intake.

Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture 2026-07-14

Watch: The $158/mo (sema) and $167/mo (tirz) headline figures are 12-month plan rates; month-to-month is $249 (sema) and $297 (tirz) — some of the widest start-to-commitment spreads in the index. Reported status from RangeYourself 2026-07-14 verification.

What neither record tells you

Ivim Health does not publish

  • no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
  • no published twelve-month tirzepatide rate
  • no semaglutide price at 0.5, 1, 1.7 mg per week
  • no published twelve-month semaglutide rate
  • no named compounding pharmacy
  • no state-by-state availability list — it says ~50 states

TMates does not publish

  • no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
  • no semaglutide price at 0.5, 1, 1.7 mg per week
  • no named compounding pharmacy
  • no state-by-state availability list — it says Confirm at intake
  • no specific cancellation or refund terms

Ask Ivim Health and TMates for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.

What would change this answer

Evidence may be upgraded. TMates carries a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.

Prepaid terms move the annual figures. TMates publishes a twelve-month rate of $167 a month against $297 month-to-month. Read those next to the cancellation terms, not the monthly rate.

Which one suits which reader

On the lowest standing monthly rate for tirzepatide, TMates Official site wins this matchup. If you want to be able to pause without still paying, tmates carries no membership; and if you would rather trust a better-evidenced number, ivim health's price rests on stronger provenance.

Both figures should be checked at the provider's own checkout before you pay. Ivim Health's tirzepatide price is provider-stated as of 2026-08-05; TMates's is reported as of 2026-07-14.

Questions

Is Ivim Health or TMates cheaper for tirzepatide?

TMates is cheaper on all-in monthly cost at 10 mg/week: $297 against $353, a difference of $56 a month. All-in means the medication plus every mandatory recurring fee.

What is the twelve-month cost of Ivim Health versus TMates?

Ivim Health works out to $4,236 across twelve months and TMates to $2,004, on the plan terms each publishes.

Does Ivim Health or TMates raise the price as the dose goes up?

Ivim Health: yes, it prices by dose. TMates: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.

How many ways do Ivim Health and TMates differ?

6 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.

Which of Ivim Health and TMates names its pharmacy?

Neither. Ivim Health records Partner pharmacies and TMates records Partner 503A pharmacy (not publicly named). Without a named pharmacy, neither program's licensing or inspection history can be checked before you order.

How well evidenced are the Ivim Health and TMates prices?

Ivim Health's tirzepatide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-05. TMates's is reported, captured 2026-07-14. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.

Which is cheaper for semaglutide?

Ivim Health, at $224 a month all-in against $249 at 2.4 mg/week. The two programs do not necessarily lead on both medications.

Official sources: Ivim Health official site · TMates official site. Compounded tirzepatide and semaglutide are not FDA-approved products.